<DOC>
	<DOC>NCT01756261</DOC>
	<brief_summary>The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and compared at baseline and at the 6 and 12 months after start of EYLEA treatment.</brief_summary>
	<brief_title>EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Patients who have been determined to start EYLEA treatment Patients who are registered to Special drug use investigation of EYLEA for AMD(Trial Number 15858) Patients who have agreed with the patient informed consent Patients who have already received EYLEA</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EYLEA</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>QOL</keyword>
</DOC>